![conference banner](/images/conference-banner.jpeg)
Abstract
The authors would like to correct Fig. 1, Fig. 3 and Fig. 5G, as errors were introduced in the preparation of these figures for publication. The authors declare that these corrections do not change the results or conclusions of this paper. We sincerely apologize for having this error in the article, and apologize for any inconvenience caused. The authors have provided corrected version of Fig. 1, Fig. 3 and Fig. 5G here.
Anti-Cancer Agents in Medicinal Chemistry
Title:Correction: Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Volume: 19 Issue: 1
Author(s): Xiao Wei, Yi Liu, Cheng Gong, Teng Ji, Xiaoshui Zhou, Taoran Zhang, Dongyi Wan, Sen Xu, Ping Jin, Xin Yang, Xiaoting Li, Ding Ma, Zongyuan Yang*Qinglei Gao*
Affiliation:
- Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030,China
- Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030,China
Abstract: The authors would like to correct Fig. 1, Fig. 3 and Fig. 5G, as errors were introduced in the preparation of these figures for publication. The authors declare that these corrections do not change the results or conclusions of this paper. We sincerely apologize for having this error in the article, and apologize for any inconvenience caused. The authors have provided corrected version of Fig. 1, Fig. 3 and Fig. 5G here.
Export Options
About this article
Cite this article as:
Wei Xiao , Liu Yi , Gong Cheng , Ji Teng , Zhou Xiaoshui , Zhang Taoran , Wan Dongyi , Xu Sen , Jin Ping , Yang Xin , Li Xiaoting, Ma Ding , Yang Zongyuan *, Gao Qinglei *, Correction: Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis, Anti-Cancer Agents in Medicinal Chemistry 2019; 19 (1) . https://dx.doi.org/10.2174/187152061901190321115425
DOI https://dx.doi.org/10.2174/187152061901190321115425 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually worldwide. GLOBOCAN 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040. In the future, female breast cancer will be the most common cancer (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that
Act as Multidrug Resistance (MDR) Reversers
Current Topics in Medicinal Chemistry Regulatory Roles of the Ubiquitin-Proteasome System in Cardiomyocyte Apoptosis
Current Molecular Medicine The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer
Current Pharmaceutical Design HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Current Medicinal Chemistry MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine Recent Progress on the Role of Fibronectin in Tumor Stromal Immunity and Immunotherapy
Current Topics in Medicinal Chemistry FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Patents on Enhancing the Potency and Longevity of Highly Valuable Protein Hormones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cellular Responses to 24R,25-dihydroxyvitamin D3 in Bone and Cartilage
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Current Pharmaceutical Design Continuous Nanostructures for the Controlled Release of Drugs
Current Pharmaceutical Design Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Critical Role of IL-8 Targeting in Gliomas
Current Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology